Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Behavioral and Pharmacologic Treatment of Binge Eating and Obesity
NCT03045341Phase 3Completed
- Sponsor
- Yale University
- Start
- Feb 2017
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of naltrexone, bupropion in binge eating disorder (BED), obesity, sponsored by Yale University. Started Feb 2017; status: completed.
02
Drugs
naltrexonebupropion
03
Conditions
binge eating disorder (BED)obesity
Beyond the preview
Go deeper on NCT03045341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03045341.